本文關(guān)鍵詞： 多西他賽 奈達(dá)鉑 晚期宮頸癌 增殖細(xì)胞核抗原 療效 安全性　出處：《中國(guó)藥房》2017年20期 　論文類(lèi)型：期刊論文

【摘要】：目的:探討奈達(dá)鉑聯(lián)合多西他賽對(duì)晚期宮頸癌患者的臨床療效及安全性。方法:回顧性選取2014年4月-2016年4月于我院就診的晚期宮頸癌患者53例,根據(jù)化療方案分為觀察組(31例)和對(duì)照組(22例)。對(duì)照組患者給予多西他賽注射液60 mg/m~2,ivgtt,qw;觀察組患者在對(duì)照組基礎(chǔ)上給予注射用奈達(dá)鉑35 mg/m~2+0.9%氯化鈉注射液稀釋至500 m L,ivgtt(≥60 min),qw。兩組患者均以21 d為1個(gè)化療周期,行2個(gè)周期化療。兩組患者治療結(jié)束2周后評(píng)價(jià)臨床療效,檢測(cè)治療前及治療結(jié)束2周后增殖細(xì)胞核抗原(PCNA)積分,并記錄不良反應(yīng)發(fā)生情況。結(jié)果:觀察組患者的總有效率(77.42%)明顯高于對(duì)照組(63.64%),差異有統(tǒng)計(jì)學(xué)意義(P0.05)。治療前,兩組患者PCNA積分比較,差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05);治療后,兩組患者PCNA積分均明顯降低,且觀察組明顯低于對(duì)照組,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。兩組患者各項(xiàng)不良反應(yīng)均集中在I度,且不良反應(yīng)發(fā)生率比較,差異均無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論:奈達(dá)鉑聯(lián)合多西他賽可明顯提高晚期宮頸癌患者的臨床療效,與多西他賽單獨(dú)使用相比,并不會(huì)增加不良反應(yīng)的發(fā)生。
[Abstract]:Objective: to investigate the clinical efficacy and safety of neidaplatin combined with docetaxel in the treatment of advanced cervical cancer. From April 2014 to April 2016, 53 patients with advanced cervical cancer were selected retrospectively. According to the chemotherapy regimen, the patients in the observation group (n = 31) and the control group (n = 22) were divided into two groups. The patients in the observation group were treated with 35 mg/m~2 0.9% sodium chloride injection for injection of nedaplatin on the basis of the control group and diluted to 500ml / d iv gtt (鈮，

本文編號(hào)：1464515